The future of the global group acyw135 meningococcal polysaccharide vaccine market looks promising with opportunities in the hospitals, clinics markets.
- Within the type category, polysaccharide vaccines is expected to witness higher growth over the forecast period due to polysaccharide vaccines are easier to store and transport.
- Within the application category, clinics is expected to witness the higher growth due to clinics are better equipped than hospitals to provide routine care.
- In terms of regions, North America is expected to witness the highest growth over the forecast period due to many international travelers from North America will require the meningococcal vaccine.
Emerging Trends in Group ACYW135 Meningococcal Polysaccharide Vaccine Market
The market for the group ACYW135 meningococcal polysaccharide vaccine is expected to change from campaign-based procurement to demand linked to risks and travel between 2025 and 2027. Affordable, long-lasting conjugate options prompt some public health agencies to consider cost trade-offs. According to Lucintel, there will be a broader use of the vaccine for institutional systems and preparedness for outbreaks.- Travel and Mass-gathering Protection: The requirement for Saudi Arabia’s 2025 Hajj included a quadrivalent vaccine, and international travelers are requesting protection for the ACYW135 vaccine prior to the pilgrimage and other mass gatherings. Coverage against four serogroups will support repeat ordering for the next 3-5 years.
- Conjugate Substitution: Gradually, more national vaccination programs are showing preference for conjugate vaccines over polysaccharide vaccines. For adult travelers and rapid-response stockpile vaccines, there is a continued need for polysaccharide vaccines. WHO remains clear in distinguishing these different needs.
- Regional Outbreak Readiness: Health authorities in Africa and the Middle East are stockpiling meningococcal vaccines to be ready for the next outbreak. The meningitis roadmap on the African continent is targeting epidemic control by 2030. Governments will increasingly purchase ACYW135 supplies through tendering.
- Supply-chain Diversification: There will be a focus on buffer stockpiles and safer supply chains to reduce the reliance on single contracts over the next 3-5 years. The interruptions in 2020-2022 have showed the importance for diversification. The main supply of the vaccine will be challenged to meet demand, but price competition should become less intense over this time as new manufacturers are qualified.
- Adult and Institutional Vaccinations: Per the CDC’s February 2025 calendar, adult and institutional vaccinations continue to include military personnel, healthcare workers and people with complement deficiencies. The schedule also continues to recommend meningococcal ACWY vaccination for defined adolescent and high-risk groups. The segmentation of risk will make the demand less correlated with the wide range of childhood vaccination programs.
Recent Developments in the Group ACYW135 Meningococcal Polysaccharide Vaccine Market
The market for the acyclic conjugate meningococcal (Men-w) polysaccharide vaccine is currently undergoing various changes. During the years 2025 to 2027, meningococcal outbreaks, preparatory procurements from the public sector, flexible vaccination schedules, and competing conjugate vaccines will be shaping the demand for this market. Lucintel anticipates a modest market growth for this vaccine to mainly consist of travel vaccine market, emergency stockpiles, and countries suffering from periodic meningococcal outbreaks.- Buying from The Public Sector: The 2025 meningitis response from Nigeria puts a greater emphasis on preparedness and the planning of emergency supplies. This also creates a greater demand for affordable ACYW135 doses (April 2025). This will positively increase the stockpiling of Men-w vaccines instead of purchasing during a meningitis outbreak.
- Substitution of Conjugate Vaccines: The World Health Organization (WHO) promotes the use of Men5CV and continues to strengthen and promote the use of meningococcal conjugate vaccines in 2025, which covers five serogroups. In the coming years, polysaccharide conjugate vaccines will likely continue to play a role for the protection against meningococcal disease in the event of high meningococcal disease incidence, temporary outbreak protection, or in the absence of effective and affordable conjugate vaccines.
- Travel Health Demand: Vaccination against meningococcal disease is a requirement for Saudi Arabia, and this requirement was maintained for Umrah and Hajj pilgrims in 2025. This creates a large, consistent market for the ACYW135 vaccine (February 2025).
- Local Production: Public health agencies from Africa and Asia are focused on developing and building regional vaccine and fill-finish capacity in order to overcome the growing meningitis-related emergencies in 2025 (June 2025). Local production will provide a more consistent supply, reduce the reliance on a single vendor, and provide more competitive procurement.
- Preference for Regulation for Broader Coverage: National meningococcal schedules that will be updated in 2026 are now comparing serogroup breadth, duration, and cost, rather than reviewing individual polysaccharide vaccines as they were in March 2026. This will result in suppliers explaining the costs associated with ACYW135 and developing combination or conjugate follow-on products.
Strategic Growth Opportunities in the Group ACYW135 Meningococcal Polysaccharide Vaccine Market
From 2024 to 2026, the ACYW135 meningococcal polysaccharide vaccine market is expected to open new commercial avenues due to rebounding travel, greater outbreak preparedness and growing immunization frameworks. Although Lucintel projects that all vaccine tenders will have pricing pressure, the firm identifies procurement localization and advanced risk-based vaccination strategies, along with differentiated vaccine delivery systems, as potential opportunities for market expansion.- Expanding Routine Immunization: Gavi’s support framework covered meningococcal vaccination in 16 high-risk African countries in January 2025. Routine immunization will convert unpredictable outbreak-based demand to more predictable demand during the next 3-5 years.
- Travel and Occupational Vaccinations: According to UN Tourism, 2024 was the first year with over 1.4 billion international travels. Airlines, mining companies and universities and other sponsors of travel will purchase group ACYW135 meningococcal polysaccharide vaccines for their travelers using organized vaccination programs, increasing private vaccine sales.
- Localized Manufacturing: During 2025, India’s biologicals sector continued growing its vaccine capacity. During 2025, domestic producers focused on public tenders and foreign vaccines markets. Local manufacturing will speed up vaccine delivery and reduce the risk associated with foreign currency in Africa, Asia and the Middle East.
- Premium Formats: During March 2025, WHO reported that meningitis vaccination will be a priority within the global roadmap, which aims to reduce (or eliminate) major diseases by 2030. Prefilled syringes and vaccines with extended shelf lives will have increased prices because of reduced waste, simpler administration during travel, and the ability to reduce waste.
- Outbreak-response Services: By March 2025, over 2,000 suspected meningitis cases were recorded by Nigeria, emphasizing the importance for rapid inventory placement. Suppliers who offer emergency inventories along with surveillance-linked forecasting and technical assistance, will earn recurring contracts beyond ad hoc interventions.
Group ACYW135 Meningococcal Polysaccharide Vaccine Market Drivers and Challenges
Technology, the economy, public health and regulation define the group acyw135 meningococcal polysaccharide vaccine market. These include factors that determine demand such as prevention of outbreaks, travel, immunization programs, and disease surveillance. Market forces also include the innovation of products, affordability, manufacturing and cold chain capacity. Lucintel indicated that the market will grow by addressing the balance of safety, financing and regulations across the developed and developing countries in order to provide greater coverage.The factors responsible for driving this market include:
- Customer Demand: Rising demand for the vaccine is due to increased international travel, attendance to universities, increased risk of outbreaks, and increased awareness of invasive meningococcal disease and military service. Demand was also sustained following continued routine vaccination of adolescents and other high-risk groups within major immunization systems in January 2025. For the next 3 to 5 years, demand of the vaccine is expected to increase because of risk communication with a focus on travel and student vaccinations. This will however depend on the efforts of public health agencies to provide preventive coverage. Demand for the vaccine will also depend on the confidence in vaccines, outbreaks, reimbursement and the perceived value associated with vaccine coverage for serogroups A, C, Y, and W.
- Public-Health Programs: Reliable supply chains for procurement of group ACYW135 products are due to government funded vaccinations campaigns and preparedness for outbreaks. In March 2025, national and regional health organizations continued stockpiling and implementing campaigns related to meningococcal vaccine preparedness and administering targeted vaccinations for at-risk populations, which involved the distribution of thousands of vaccines. Looking ahead, the next 3-5 years may see improved stability of the market as a result of improved surveillance, emergency response, and integration of adolescent and travel health programs. Still, procurement of group ACYW135 products may continue to be irregular, as governments typically purchase large stocks of vaccines following outbreaks, changes in the seasonal risk, quarantines, or after new risk assessments are made.
- Regulatory Support: Greater confidence in quadrivalent meningococcal vaccines may be attributed to clearer licensing pathways, standardized public procurement, and supportive recommendations from health authorities. In February 2025, regulators and health agencies continued to require documented evidence of quality, safety, potency, and stability before approving or procuring meningococcal products. During the next 3-5 years, shorter registration time frames and improved market access may be the likely outcomes of harmonized regulations and greater acceptance of international standards. It is likely that manufacturers will need strong evidence and post marketing surveillance, as the market for polysaccharide formulations may be greatly impacted by changes in recommendations and preferences for conjugated vaccines.
- Manufacturing Efficiency: Optimizations in the subsequent stages of antigen production and in the planning of antigen supply will decrease shortages and improve the reliability of delivery. In April 2025, multiyear supply planning of tens of thousands of doses continued to be used by manufacturers and public buyers in campaign support for vulnerable regions expected to experience outbreaks. It is anticipated that optimization of existing capacity and the implementation of regional fill-and-finish operations and digital inventory control systems over the next 3-5 years will minimize wastage and increase responsiveness. Sterility, consistency, and the cold chain requirements of polysaccharide vaccines will be more challenging to meet due to increased competition from conjugate vaccines.
- Infrastructure Investment: Vaccination accessibility is improved by the building of health facilities, vaccination clinics, laboratories, and the strengthening and extension of the cold chain and disease surveillance. Investments made by public health initiatives in May 2025 in emerging markets to include temperature-controlled distributions and mobile vaccinations to reach and support campaigns higher than one hundred thousand doses were continued. It is expected that the creation of market accessibilities and the improvement of surveillance of disease outbreaks will be the greatest impact of infrastructure investments in the next 3-5 years, especially when government procurement is synchronized with the provision of health workers, electricity, digital registrations, and community-based vaccinations.
The challenges facing this market include:
- Product Substitution: Polysaccharide vaccines are being replaced by conjugate vaccines, as the latter elicits longer-lasting protection, and are preferred for routine and extended protection. By June 2025, there were ongoing evaluations of conjugate vaccines’ substitutability for adolescent and high-risk populations, and many programs were seeking shorter and longer durability, respectively, of protection. In the next three to five years, it is likely that this substitution will reduce the growth of the group ACYW135 meningococcal polysaccharide vaccines in the higher-income countries. However, in this period of time, there may be opportunities in outbreak control, travel vaccinations, and in the developing countries for polysaccharide products, as long as the manufacturers maintain low costs and improve the convenience of their products.
- Affordability and Access: In low- and middle-income countries, vaccinations are limited due to high procurement costs, long and expensive transport, limited insurance coverage, and poor cold-chain infrastructure. By July 2025, most public health vaccination programs in various regions continued to prioritize funding routine coverage vaccinations, and many meningococcal vaccination programs became dependent on external funding, including emergency funding. In the next three to five years, it is expected that significant differences in buying power will lead to large variations in the growth of this market across different global regions. Manufacturers will likely be required to implement several access-improving mechanisms, including local partnerships, tailored pricing, intense competition for procurement, highest possible funding coverage, and lower costs, to sustain supply.
- Supply and Regulatory Uncertainty: There are complexities in production, few qualified suppliers, irregular disease outbreaks, and continually changing recommendations, all of which can affect demand. In August 2025, procurement agencies continued to monitor stock levels and delivery of meningococcal vaccines, as some campaigns had to rapidly refill with over 50,000 doses. For the next 3 to 5 years, manufacturers may struggle to meet their normal contract obligations due to the demands caused by sudden outbreaks. Due to delays in approvals, inspections, and material availability, batches can even be held, which will contribute to even more shortages. Manufacturers also run the risk of having insufficient capacity due to uncertain buying needs.
List of Group ACYW135 Meningococcal Polysaccharide Vaccine Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies group acyw135 meningococcal polysaccharide vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the group acyw135 meningococcal polysaccharide vaccine market companies profiled in this report include:
- Pfizer Inc.
- Sanofi Pasteur
- GlaxoSmithKline
- Novartis
- Hualon Biological Engineering Inc.
Group ACYW135 Meningococcal Polysaccharide Vaccine Market by Segment
The study includes a forecast for the global group acyw135 meningococcal polysaccharide vaccine market by type, application, and region.Type [Value ($B) from 2019 to 2035]:
- Polysaccharide Vaccines
- Conjugated Vaccines
Application [Value ($B) from 2019 to 2035]:
- Hospitals
- Clinics
Region [Value ($B) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Group ACYW135 Meningococcal Polysaccharide Vaccine Market
The market for the ACYW135 Meningococcal Polysaccharide Vaccine continues to be influenced by Public immunization schedules, Outbreak preparedness, and manufacturer product portfolios. For the 2025 to 2027 timeframe, procurement agencies will purchase the established Polysaccharide supply vs the longer duration Conjugate supply. Per the recent update from Lucintel, the primary country Level policies and supplier commitments will influence market growth for the foreseen future.- United States: The 2025 adult immunization schedule for the CDC continued vaccination of the defined risk groups for travel and splenic dysfunction which included the use of MenACWY. Both MenQuadfi (Sanofi) and Menveo (Pfizer) continued to be licensed as ACWY products. This sustained demand for Institutional use and retained a potential replacement market for the next three to five years.
- China: China's public procurement continued national program immunization with two doses of a Meningococcal Polysaccharide vaccine, with later booster doses scheduled for regular childhood immunization, and a 14 vaccine category program for 2025 (January). The continued governmental procurement will maintain a market for the local manufacturers to produce AVWY vaccines.
- Germany: In 2025, STIKO renewed recommendations for risk-based vaccination of MenACWY for travelers and the medically vulnerable, as well as 18 routine recommendations for vaccination (January). This policy will maintain an emphasis on travel, occupational, and high-risk market entitlement vs mass procurement of the general child population.
- India: The WHO prequalified Serum Institute of India’s five-valent meningococcal conjugate vaccine, Men Five. At the time of the vaccine’s release, only serogroups A, C, W and Y were covered. Now, with the addition of serogroup X, the public-sector supply for vaccine-preventable meningococcal disease in Africa and other markets is further strengthened. This may also foster a shift away from contract-based procurement of individual polysaccharide vaccines.
- Japan: Private and travel-related markets helped maintain market access in Japan for a quadrivalent MenACWY vaccine. However, meningococcal vaccinations still do not have a place in the routine national program. Japan’s routine program does, however, include 16 vaccine-preventable diseases, as of April 2025. There will be insufficient universal funding to meet domestic demands, but there will be sufficient demand to meet the needs of a specialized clientele and outbound travel.
Features of the Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market
- Market Size Estimates: group acyw135 meningococcal polysaccharide vaccine market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2025 to 2031) by various segments and regions.
- Segmentation Analysis: group acyw135 meningococcal polysaccharide vaccine market size by type, application, and region in terms of value ($B).
- Regional Analysis: group acyw135 meningococcal polysaccharide vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the group acyw135 meningococcal polysaccharide vaccine market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the group acyw135 meningococcal polysaccharide vaccine market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the group acyw135 meningococcal polysaccharide vaccine market by type (polysaccharide vaccines and conjugated vaccines), application (hospitals and clinics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Pfizer Inc.
- Sanofi Pasteur
- GlaxoSmithKline
- Novartis
- Hualon Biological Engineering Inc.
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

